Our mission is to support the development of Clinical Psychology, both as a profession and as a body of knowledge and skills. By working collaboratively with a number of organisations including the ...

This post is part of MoFo’s 2025 Intersection of AI and Life Sciences blog series. In this blog series, we explore how ...

The FDA says that food companies will have until Jan. 15, 2027 to stop using the dye. Drugmakers will have an extra year, until January 2028, to comply with the change. Red 3, also known as ...

In this video interview, Kimberly Tableman, founder & CEO, ESPERO, discusses historical challenges with long protocol development timelines and how they can be addressed. In a recent video interview ...

Creating two distinct classifications of “clinical obesity” and “pre-clinical obesity” would provide more accurate diagnosis and more personalised treatment, it argued.

Jan. 14 (UPI) --The U.S. Food and Drug Administration hopes "front-of-package" labeling will better improve the American population's health, the FDA announced. "Food should be a vehicle for ...

Regulated by authorities such as the FDA as ‘Software as a Medical Device’ (SaMD), PDTs are ... ‘s DREAM study demonstrates the potential for PDTs to achieve sustained clinical impact in real-world ...

MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases with a market capitalization of $74 million, announced today that the U.S.

Annovis Bio (ANVS) announced that the FDA has accepted an updated protocol for the pivotal Phase 3 Alzheimer’s Disease study, which is slated to begin in January 2025. In October 2024 ...

(NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform ... disease (PD), today announced that the FDA has accepted an updated protocol for the pivotal Phase 3 AD study ...